Novo Nordisk is now offering its anti-obesity drug for as low as $199 per month

Core Insights - Novo Nordisk has implemented significant price reductions for its leading GLP-1 medications, Wegovy and Ozempic, allowing patients to access the lowest doses for only $199 per month [1] Pricing Strategy - The new pricing strategy targets cash-paying patients, making these medications more affordable and accessible [1] Market Impact - This move is expected to enhance patient access to these popular weight management and diabetes treatment drugs, potentially increasing market share for Novo Nordisk [1]